ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 141 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 2.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $277,000 | -86.6% | 14,709 | -91.6% | 0.00% | -100.0% |
| Q2 2019 | $2,068,000 | -31.2% | 175,664 | -20.2% | 0.00% | -40.0% |
| Q1 2019 | $3,004,000 | +38.8% | 220,064 | +4.2% | 0.01% | +25.0% |
| Q4 2018 | $2,165,000 | -33.5% | 211,183 | +7.9% | 0.00% | -20.0% |
| Q3 2018 | $3,258,000 | +147.6% | 195,695 | +134.9% | 0.01% | +150.0% |
| Q2 2018 | $1,316,000 | +122.7% | 83,300 | +79.1% | 0.00% | +100.0% |
| Q1 2018 | $591,000 | +14.8% | 46,500 | +3.3% | 0.00% | 0.0% |
| Q4 2017 | $515,000 | +3.8% | 45,000 | +11.1% | 0.00% | 0.0% |
| Q3 2017 | $496,000 | +1.4% | 40,500 | -5.2% | 0.00% | 0.0% |
| Q2 2017 | $489,000 | +37.4% | 42,700 | +149.7% | 0.00% | 0.0% |
| Q1 2017 | $356,000 | -15.2% | 17,100 | -15.3% | 0.00% | 0.0% |
| Q4 2016 | $420,000 | +7.4% | 20,200 | +69.3% | 0.00% | 0.0% |
| Q3 2016 | $391,000 | – | 11,931 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 2,942,203 | $36,042,000 | 9.93% |
| Foresite Capital Management II, LLC | 1,043,832 | $12,787,000 | 5.18% |
| Redmile Group, LLC | 6,476,766 | $79,340,000 | 3.91% |
| DAFNA Capital Management LLC | 346,013 | $4,239,000 | 2.63% |
| Cormorant Asset Management, LP | 900,000 | $11,025,000 | 1.95% |
| SENZAR ASSET MANAGEMENT, LLC | 641,170 | $7,854,000 | 1.92% |
| Asymmetry Capital Management, L.P. | 105,228 | $1,289,000 | 1.50% |
| New Leaf Venture Partners, L.L.C. | 171,364 | $2,099,000 | 0.97% |
| EMERALD ADVISERS, LLC | 1,578,477 | $19,336,000 | 0.79% |
| BB BIOTECH AG | 2,266,008 | $27,759,000 | 0.77% |